NO180636C - Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1 - Google Patents

Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1

Info

Publication number
NO180636C
NO180636C NO910669A NO910669A NO180636C NO 180636 C NO180636 C NO 180636C NO 910669 A NO910669 A NO 910669A NO 910669 A NO910669 A NO 910669A NO 180636 C NO180636 C NO 180636C
Authority
NO
Norway
Prior art keywords
igf
glycosylated
pure
preparation
glycosylated igf
Prior art date
Application number
NO910669A
Other languages
English (en)
Norwegian (no)
Other versions
NO180636B (no
NO910669D0 (no
NO910669L (no
Inventor
Anna Skottner-Lundin
Linda Fryklund
Paer Gellerfors
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of NO910669D0 publication Critical patent/NO910669D0/no
Publication of NO910669L publication Critical patent/NO910669L/no
Publication of NO180636B publication Critical patent/NO180636B/no
Publication of NO180636C publication Critical patent/NO180636C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO910669A 1988-08-20 1991-02-19 Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1 NO180636C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888819826A GB8819826D0 (en) 1988-08-20 1988-08-20 Glycosylated igf-1
PCT/EP1989/000972 WO1990002198A1 (en) 1988-08-20 1989-08-17 O-glycosylated igf-1

Publications (4)

Publication Number Publication Date
NO910669D0 NO910669D0 (no) 1991-02-19
NO910669L NO910669L (no) 1991-02-19
NO180636B NO180636B (no) 1997-02-10
NO180636C true NO180636C (no) 1997-05-21

Family

ID=10642464

Family Applications (1)

Application Number Title Priority Date Filing Date
NO910669A NO180636C (no) 1988-08-20 1991-02-19 Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1

Country Status (15)

Country Link
US (1) US5273966A (da)
EP (2) EP0429502A1 (da)
JP (1) JP2543998B2 (da)
AT (1) ATE109206T1 (da)
AU (1) AU623675B2 (da)
CA (1) CA1335802C (da)
DE (1) DE68917061T2 (da)
DK (1) DK175360B1 (da)
ES (1) ES2060778T3 (da)
FI (1) FI102282B1 (da)
GB (1) GB8819826D0 (da)
IE (1) IE65096B1 (da)
NO (1) NO180636C (da)
NZ (1) NZ230383A (da)
WO (1) WO1990002198A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5231178A (en) * 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
EP0578746B1 (en) * 1991-04-01 2002-07-03 Merck & Co., Inc. GENES WHICH INFLUENCE $i(PICHIA) PROTEOLYTIC ACTIVITY, AND USES THEREFOR
EP0600372B1 (de) * 1992-12-02 1997-02-05 Hoechst Aktiengesellschaft Verfahren zur Gewinnung von Proinsulin mit korrekt verbundenen Cystinbrücken
SE9402332D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab Igf-1
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
CL2007001614A1 (es) * 2006-06-09 2008-08-08 Novartis Ag Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
WO2011053545A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Granulocyte-colony stimulating factor produced in glycoengineered pichia pastoris
US20100172865A1 (en) * 2010-03-18 2010-07-08 Shantha Totada R Methods of enhancing hair growth
JP6200806B2 (ja) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
KR20160091888A (ko) 2013-10-02 2016-08-03 노파르티스 아게 요법에 사용하기 위한 인슐린-유사 성장 인자 모방체
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486216T2 (de) * 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.

Also Published As

Publication number Publication date
ES2060778T3 (es) 1994-12-01
FI102282B (fi) 1998-11-13
NO180636B (no) 1997-02-10
ATE109206T1 (de) 1994-08-15
GB8819826D0 (en) 1988-09-21
DK29491D0 (da) 1991-02-20
DE68917061T2 (de) 1994-11-17
EP0360411A1 (en) 1990-03-28
JPH05505514A (ja) 1993-08-19
DK175360B1 (da) 2004-09-13
EP0429502A1 (en) 1991-06-05
US5273966A (en) 1993-12-28
DK29491A (da) 1991-04-19
NO910669D0 (no) 1991-02-19
AU4051889A (en) 1990-03-23
NZ230383A (en) 1992-01-29
DE68917061D1 (de) 1994-09-01
EP0360411B1 (en) 1994-07-27
JP2543998B2 (ja) 1996-10-16
FI102282B1 (fi) 1998-11-13
IE65096B1 (en) 1995-10-04
FI910795A0 (fi) 1991-02-19
AU623675B2 (en) 1992-05-21
WO1990002198A1 (en) 1990-03-08
CA1335802C (en) 1995-06-06
NO910669L (no) 1991-02-19
IE892652L (en) 1990-02-20

Similar Documents

Publication Publication Date Title
NO973848D0 (no) Fremgangsmåte til fremstilling av hemoglobinliknende protein
AU6701890A (en) Process for the production of biologically active protein
MY108496A (en) Hypoglycemic thiazolidine diones.
ATE103914T1 (de) Neue thienylcarbonsaeureester von aminoalkoholen, ihre quaternierungsprodukte sowie die herstellung und verwendung dieser verbindungen.
DE68916385D1 (de) Stabilisierte Formulierungen mit hydrohoben Proteinen.
AU7184487A (en) Human g-csf protein expression
AU6733487A (en) Mammalian interleukin-4
ATE56728T1 (de) Neue polypeptide mit alpha-amylase-hemmender wirkung, verfahren zu deren herstellung, deren verwendung und pharmazeutische praeparate.
NO180636C (no) Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1
DE68909077D1 (de) Gamma-Linolensäure oder Dihomo-gamma-Linolensäure enthaltende Zubereitung zur Verbesserung der Haut.
CA2066618A1 (en) Plasmids containing dna encoding the amino acid sequence of tcf-ii, transformed cells with the plasmids, and production method of biologically active substance using the transformed cells
KR900700492A (ko) N-헤테로사이클릭 프로필리덴-1,1-비스포스폰산, 이의 제조방법 및 약제학적 조성물
DE69001573D1 (de) Zusammensetzungen zur herstellung von in dosisformen aktiven vitaminen d3 sowie verfahren zur herstellung stabiler, in dosisformen aktiver vitamine d3 unter deren verwendung.
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
FI945626A0 (fi) Menetelmä 2,2-difluoriketeenisilyyliasetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihappoestereiden valmistamiseksi
PT80752A (en) Process for preparing solid medicament formulations containing dihydropyridines
IS1697B (is) Hliðstæð aðferð til framleiðslu á 3,3'-dithiobis (própíónsýrum) og esterum þeirra
DE3685044D1 (de) Analoge interferon-polypeptide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
EP0390849A4 (en) Methyl cellulose pharmaceutical composition
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
EP0246861A3 (en) Pharmaceutical composition based on crotoxine, process for preparing the active component and the pharmaceutical composition
EP0351876A3 (en) Composition for potentiating vaccination effect
DE2965364D1 (en) Alpha-difluoromethyl amino acids and pharmaceutical composition containing the same
DE3585936D1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
EP0351017A3 (en) Pharmaceutical composition useful for the treatment of cardiovascular diseases